We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Selexis Announces Expansion of R&D License Agreement with Amgen
News

Selexis Announces Expansion of R&D License Agreement with Amgen

Selexis Announces Expansion of R&D License Agreement with Amgen
News

Selexis Announces Expansion of R&D License Agreement with Amgen

Read time:
 

Selexis SA has announced that Amgen has expanded their R&D License Agreement with Selexis to include an evaluation of the proprietary Selexis SURE CHO-M Cell Line™ for research and development.

Under the agreement, Amgen will be able to evaluate the SURE CHO-M Cell Line™ in conjunction with the Selexis SUREtech Vectors™ for improved R&D.

“Successful protein expression in R&D is dependent upon a cell line development platform that is robust, high-yielding and stable,” said Igor Fisch, Ph.D., President and CEO of Selexis.

Fisch continued, “Selexis is continually optimizing its proprietary cell line and technology platform to enable partners such as Amgen to make better R&D decisions by generating reliable data points faster and more cost efficiently. This current agreement is built on the long-standing relationship between our two companies since 2004.”

Advertisement